hemophilianewstoday.com /2 days ago

Preventive treatment curbs bleeding in mild, moderate hemophilia A

Preventive treatment with Hemlibra (emicizumab-kxwh) kept bleeding under control for nearly three years in people with mild or moderate hemophilia A without inhibitors. That’s acco...

Read source
hemophilianewstoday.com /1 month ago

Low-dose treatment cuts bleeds in kids with hemophilia A

Preventive treatment with low-dose Hemlibra (emicizumab-KXWH) significantly reduced bleeding and improved quality of life in young children with hemophilia A, regardless of inhibit...

Read source
hemophilianewstoday.com /2 weeks ago

Weekly infusion reduces bleeding in boys with hemophilia A

Once-weekly preventive treatment with Altuviiio (efanesoctocog alfa) safely reduced bleeding rates while maintaining protective clotting factor levels without triggering neutralizi...

Read source
hemophilianewstoday.com /5 days ago

New injection therapy for hemophilia A, Frehemgo, wins approval in Europe

The injection therapy denecimig for hemophilia A — designed to prevent bleeding episodes in adults and children with or without inhibitors — has been approved in the European Union...

Read source
thehindubusinessline.com /1 month ago

Sanofi gets CDSCO nod for drug to prevent bleeding in haemophilia patients

CDSCO approval covers adults and adolescents 12+ with or without factor VIII or IX inhibitors, Sanofi India said

Read source
hemophilianewstoday.com /1 month ago

Oral hemophilia A treatment shows promise in preclinical studies

Inno8, a potential oral treatment to prevent bleeds in people with hemophilia A, appears more potent and long-lasting than currently available injectable treatments in preclinical...

Read source
biopharmadive.com /1 week ago

Bayer wins FDA nod for a new kind of blood thinner

Sunharbo’s U.S. approval is the first for a “Factor XIa” inhibitor, an anticipated class of medicines seen as a possible step forward in stroke prevention. 

Read source
hemophilianewstoday.com /1 week ago

FDA clears clinical trial of gene-editing therapy for hemophilia A

The U.S. Food and Drug Administration (FDA) has given the go-ahead for Metagenomi Therapeutics to start a first-in-human clinical trial testing MGX-001, the company’s experimental...

Read source
hemophilianewstoday.com /1 month ago

More than half with hemophilia had gaps in prescribed factor treatment

More than half of people with hemophilia receiving prophylactic (preventive) factor replacement therapies at two treatment centers in Brazil did not collect enough medication to fo...

Read source
hemophilianewstoday.com /1 month ago

Hemophilia A drives healthcare costs higher, says study in Canada

Hemophilia A patients rack up high hospital bills, driving costs for the healthcare system higher, a study from Canada showed. “This study confirms that even with improved [treatme...

Read source
hemophilianewstoday.com /1 month ago

Blood tests may vary in measuring factor VIII after treatment

Blood tests can give different readings of factor VIII (FVIII) activity after treatment with Altuvoct (efanesoctocog alfa), marketed as Altuviiio in the U.S., a study found. The di...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.